Glaukos wins iStent nod Down Under

Glaukos (NYSE:GKOS) said today it won approval from the Australian Therapeutic Goods Administration for its iStent Inject trabecular micro-bypass stent designed for use in cataract surgeries to treat glaucoma.

The device is indicated for the reduction of intraocular pressure in adult patients with mild-to-moderate glaucoma who are currently being treated with ocular hypotensive medication, the Laguna Hills, Calif-based company said.

Glaukos’ iStent Inject, made from non-ferromagnetic titanium and coated in heparin, is designed to be implanted into multiple trabecular meshwork through a single corneal entry point to reduce IOP, The company said.

“The iStent inject is designed to make it more straightforward for a surgeon to implant two stents in a facile click-and-release motion, providing an important new tool for effectively managing patients’ IOP. This approval strengthens our offering to Australian surgeons and patients, and underscores our commitment to expand our presence in the Asia Pacific region,” CEO Thomas Burns said in a press release.

Earlier this month, Glaukos closed its $140 million initial public offering with it underwriters exercising their over-allotment option, meaning net proceeds for the glaucoma device maker of roughly $112.3 million.

The post Glaukos wins iStent nod Down Under appeared first on MassDevice.

from MassDevice http://ift.tt/1IuDTcb